Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Identification of epitopes in ovalbumin that provide insights for cancer neoepitopes
Sukrut Hemant Karandikar, … , Alan Jerry Korman, Pramod Kumar Srivastava
Sukrut Hemant Karandikar, … , Alan Jerry Korman, Pramod Kumar Srivastava
Published March 14, 2019
Citation Information: JCI Insight. 2019;4(8):e127882. https://doi.org/10.1172/jci.insight.127882.
View: Text | PDF
Research Article Immunology

Identification of epitopes in ovalbumin that provide insights for cancer neoepitopes

  • Text
  • PDF
Abstract

MHC I–restricted epitopes of chicken ovalbumin (OVA) were originally identified using CD8+ T cells as probes. Here, using bioinformatics tools, we identify 4 additional epitopes in OVA in addition to a cryptic epitope. Each additional epitope is presented in vivo, as deduced from the lack of CD8+ T cell response to it in OVA-transgenic mice. In addition, CD8 responses to the previously known epitopes and those identified in this study are examined in C57BL/6J mice exposed to the OVA-expressing tumor E.G7 in several ways. No responses to any epitope, including SIINFEKL, are detected in mice with growing E.G7 or mice immunized with the tumor. Only in E.G7-bearing mice treated with an anti–CTLA-4 antibody, which depletes tumor-infiltrating regulatory T cells, are CD8 responses to SIINFEKL and the epitope EKYNLTSVL identified in this study detected. Finally, all epitopes fail to treat mice with preexisting tumors. These observations force an important reconsideration of the common assumptions about the therapeutic value of neoepitopes detected by CD8 responses in tumor-bearing hosts.

Authors

Sukrut Hemant Karandikar, John Sidney, Alessandro Sette, Mark Joseph Selby, Alan Jerry Korman, Pramod Kumar Srivastava

×

Full Text PDF | Download (3.31 MB)


Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts